# A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

> **NCT02213146** · PHASE1,PHASE2 · COMPLETED · sponsor: **Adocia** · enrollment: 38 (actual)

## Conditions studied

- Diabetes Mellitus Type 1

## Interventions

- **DRUG:** BioChaperone human insulin
- **DRUG:** Huminsulin® Normal
- **DRUG:** Humalog®

## Key facts

- **NCT ID:** NCT02213146
- **Lead sponsor:** Adocia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-12
- **Final completion:** 2015-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213146, "A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02213146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*